John Holyoake, Vice President, Investment Banking, joined Bloom Burton & Co. in January 2012. At Bloom Burton, John’s responsibilities include M&A advisory, licensing advisory and monetization planning, as well as conducting technical and commercial due diligence on companies across all healthcare sectors. John’s area of expertise spans early-stage technologies to profitable healthcare service companies, with a particular focus on preclinical-stage biotech.

John is a member of the Board of Directors of Triumvira Immunologics Inc., and Appili Therapeutics Inc. Additionally, John is a member of the Core Evaluation Team for Genome Canada’s Genomic Applications Partnership Program and sits on the TOHealth Risk Capital Committee.

Before joining Bloom Burton & Co, Dr. Holyoake worked at TenX Biopharma, a clinical stage oncology company and at the life science consulting group SHI Link. John holds a Master’s in Biochemistry from the University of Oxford, received a doctorate from the same institution and made the transition across the Atlantic for a post-doctoral research fellowship at The Hospital for Sick Children, Toronto.